Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MITO

Stealth BioTherapeutics (MITO) Stock Price, News & Analysis

Stealth BioTherapeutics logo

About Stealth BioTherapeutics Stock (NASDAQ:MITO)

Advanced Chart

Key Stats

Today's Range
$0.32
$0.32
50-Day Range
$0.31
$0.32
52-Week Range
$0.16
$1.03
Volume
N/A
Average Volume
946,105 shs
Market Capitalization
$23.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Receive MITO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MITO Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Bolt Biotherapeutics Inc
See More Headlines

MITO Stock Analysis - Frequently Asked Questions

Stealth BioTherapeutics Corp (NASDAQ:MITO) released its quarterly earnings results on Thursday, August, 5th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01.

Stealth BioTherapeutics (MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets served as the underwriters for the IPO and Nomura was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stealth BioTherapeutics investors own include Tesla (TSLA), TherapeuticsMD (TXMD), NIO (NIO), Plug Power (PLUG), Allena Pharmaceuticals (ALNA), SCYNEXIS (SCYX) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Last Earnings
8/05/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MITO
Fax
N/A
Employees
29
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$52.53 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.09 million
Price / Cash Flow
N/A
Book Value
($0.79) per share
Price / Book
-0.41

Miscellaneous

Free Float
N/A
Market Cap
$23.54 million
Optionable
Not Optionable
Beta
1.46
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:MITO) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners